The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Blood Protein Disorders Bone Marrow Diseases Cardiovascular Diseases Chronic Disease Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Disease Attributes Germ Cell Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Hodgkin Disease Hodgkin's Disease Immune System Diseases Immunodeficiency Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Leukemia, Myeloid, Acute Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Plasma Cell Non-Hodgkin's Lymphoma Paraproteinemias Pathologic Processes Pathological Conditions, Signs and Symptoms Precursor Cell Lymphoblastic Leukemia-Lymphoma Vascular Diseases

Age range

18 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Wake Forest Baptist Health

Winston-Salem, North Carolina, 27157, United States

Location status: Recruiting

Location contact

David Hurd, MD

CONTACT

[email protected]

336-716-2843

David Hurd, MD

PRINCIPAL_INVESTIGATOR

About this study

To provide an IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant or cellular therapies for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.

To provide a consent mechanism for the retrospective study of cellular products, when available, if there is a specific question to be addressed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant

Exclusion criteria

Participation in any other treatment research protocol

Treatment and study plan

Primary outcomes

Data followup

Time frame: 1 year

Gather basic survival and complication data for operational and research databases for ongoing regulatory and future operational queries

Study contacts

Contact information is provided by the study sponsor or research team.

Dianna Howard, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Official study title

The Prospective Collection, Storage and Reporting of Data on Patients

Important dates

Study start: 2001
Primary completion: 2026
Study completion: 2026
First posted: Jul 1, 2013
Registry last updated: Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed